Targeted nanoparticle delivery of doxorubicin into placental tissues to treat ectopic pregnancies

TJ Kaitu'u-Lino; S Pattison; L Ye; L Tuohey; P Sluka; J MacDiarmid; H Brahmbhatt; T Johns; AW Horne; J Brown; S Tong

Journal article

Targeted nanoparticle delivery of doxorubicin into placental tissues to treat ectopic pregnancies

TJ Kaitu'u-Lino, S Pattison, L Ye, L Tuohey, P Sluka, J MacDiarmid, H Brahmbhatt, T Johns, AW Horne, J Brown, S Tong

Endocrinology | Published : 2013

DOI: 10.1210/en.2012-1832

Abstract

Abnormal trophoblast growth can cause life-threatening disorders such as ectopic pregnancy, choriocarcinoma, and placenta accreta. EnGeneIC Delivery Vehicles (EDVs) are nanocells that can promote tissue-specific delivery of drugs and may be useful to medically treat such disorders. The objective of this study was to determine whether EDVs loaded with the chemotherapeutic doxorubicin and targeting the epidermal growth factor receptor (EGFR, very highly expressed on the placental surface) can regress placental cells in vitro, ex vivo, and in vivo. In female SCID mice, EGFR-targeted EDVs induced greater inhibition of JEG-3 (choriocarcinoma cells) tumor xenografts, compared with EDVs targeting a..

View full abstract

University of Melbourne Researchers

Tu'uhevaha Kaitu'u-Lino Author

Louie Ye Author

Stephen Tong Author

Steven Tong Author

Related Projects (3)

CAREER DEVELOPMENT AWARD - CLINICAL

Recent evidence has pointed to the beginning of pregnancy as the time when biological cascades begin that cause common diseases of pregnancy..

DEVELOPMENT OF NOVEL MEDICAL THERAPIES TO CURE ECTOPIC PREGNANCIES

Ectopic pregnancies are conceptions implanting outside the womb, mainly the fallopian tube. They are pathological, and can erode straight th..

AUSTRALIAN BASED BIOMEDICAL FELLOWSHIP

The endometrium (lining of the uterus) undergoes breakdown and re-growth each month as part of the menstrual cycle. This restorative process..

Grants

Awarded by Medical Research Council

Funding Acknowledgements

This study was financially supported by The National Health and Medical Research Council of Australia (Project Grant No. 606611; Salary support No. 490970, No. 490995); Helen MacPherson Trust; Strategic Grants Scheme Monash University; and The Victorian Government's Operational Infrastructure Support Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.